📊 OVID Key Takeaways
Is Ovid Therapeutics Inc. (OVID) a Good Investment?
Ovid Therapeutics is a pre-revenue pharmaceutical company with zero commercial sales despite significant operating losses of $17.8M and negative free cash flow. While the balance sheet is fortress-like with $94.1M cash, no debt, and $198.3M equity, the company lacks fundamental profitability drivers and is burning ~$13.9M annually with no revenue offset, creating execution risk despite 6-7 year cash runway.
Ovid’s fundamentals show a sharp revenue uptick but the business remains far from profitability, with deeply negative operating and free cash flow margins. Despite a debt‑free balance sheet and strong current ratio, reported cash is modest relative to the burn, indicating elevated financing risk unless revenue becomes more durable.
Ovid Therapeutics Inc. Key Strengths (OVID)
- Fortress balance sheet with $198.3M stockholders equity and zero debt
- Strong liquidity position with $94.1M cash and 10.17x current ratio enabling 6-7 year operational runway
- Minimal capital requirements (zero capex) reduces funding needs for development phase
- Debt-free balance sheet with low liabilities
- Very strong liquidity (8.97x current and quick ratios)
- Improving net loss and EPS alongside triple-digit revenue growth
OVID Stock Risks: Ovid Therapeutics Inc. Investment Risks
- Zero revenue with no clear commercialization timeline - pre-clinical/early development stage
- Significant negative cash flow (-$13.9M) and operating losses (-$17.8M) destroying shareholder value
- Clinical trial execution risk and inherent biotech failure rate - unproven pipeline efficacy
- Potential need for dilutive equity financing if cash runway extends beyond 6-7 years
- Negative returns (ROE -8.6%, ROA -7.5%) indicate value destruction in current phase
- Sustained operating losses (operating margin -585%) and large negative FCF
- Potential need for external financing given cash $13.15M vs. -$38.33M OCF
- Low and potentially volatile revenue base (quality/visibility concerns)
Key Metrics to Watch
- Cash burn rate trajectory - critical for survival and dilution risk
- Clinical trial milestones and FDA regulatory progress for pipeline candidates
- Time to first revenue generation and commercial product approval
- Operating loss trend and cost management relative to cash depletion
- Cash position and insider buying/selling patterns for management conviction signals
- Operating cash flow (burn rate)
- Cash and short-term investments (runway)
Ovid Therapeutics Inc. (OVID) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.17x current ratio provides a solid financial cushion.
OVID Profit Margin, ROE & Profitability Analysis
OVID vs Healthcare Sector: How Ovid Therapeutics Inc. Compares
How Ovid Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ovid Therapeutics Inc. Stock Overvalued? OVID Valuation Analysis 2026
Based on fundamental analysis, Ovid Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ovid Therapeutics Inc. Balance Sheet: OVID Debt, Cash & Liquidity
OVID Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ovid Therapeutics Inc.'s revenue has declined by 97% over the 5-year period, indicating business contraction. The most recent EPS of $-0.77 indicates the company is currently unprofitable.
OVID Revenue Growth, EPS Growth & YoY Performance
OVID Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$10.2M | N/A |
| Q3 2025 | $132.0K | -$4.7M | N/A |
| Q2 2025 | $169.0K | -$3.2M | N/A |
| Q1 2025 | $130.0K | -$10.2M | N/A |
| Q3 2024 | $109.0K | $8.5M | $-0.16 |
| Q2 2024 | $75.0K | -$3.2M | $-0.04 |
| Q1 2024 | $66.0K | -$11.7M | $-0.17 |
| Q3 2023 | $11.1K | -$11.3M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ovid Therapeutics Inc. Dividends, Buybacks & Capital Allocation
OVID SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ovid Therapeutics Inc. (CIK: 0001636651)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OVID
What is the AI rating for OVID?
Ovid Therapeutics Inc. (OVID) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OVID's key strengths?
Claude: Fortress balance sheet with $198.3M stockholders equity and zero debt. Strong liquidity position with $94.1M cash and 10.17x current ratio enabling 6-7 year operational runway. ChatGPT: Debt-free balance sheet with low liabilities. Very strong liquidity (8.97x current and quick ratios).
What are the risks of investing in OVID?
Claude: Zero revenue with no clear commercialization timeline - pre-clinical/early development stage. Significant negative cash flow (-$13.9M) and operating losses (-$17.8M) destroying shareholder value. ChatGPT: Sustained operating losses (operating margin -585%) and large negative FCF. Potential need for external financing given cash $13.15M vs. -$38.33M OCF.
What is OVID's revenue and growth?
Ovid Therapeutics Inc. reported revenue of $0.0.
Does OVID pay dividends?
Ovid Therapeutics Inc. does not currently pay dividends.
Where can I find OVID SEC filings?
Official SEC filings for Ovid Therapeutics Inc. (CIK: 0001636651) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OVID's EPS?
Ovid Therapeutics Inc. has a diluted EPS of $-0.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is OVID's fundamental grade?
Based on our AI fundamental analysis in May 2026, Ovid Therapeutics Inc. has a C grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is OVID stock overvalued or undervalued?
Valuation metrics for OVID: ROE of -8.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is OVID's AI grade for 2026?
Our dual AI analysis gives Ovid Therapeutics Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OVID's free cash flow?
Ovid Therapeutics Inc.'s operating cash flow is $-13.9M, with capital expenditures of $0.0.
How does OVID compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -8.6% (avg: 15%), current ratio 10.17 (avg: 2).